These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17620751)

  • 41. AIDS in Brazilian children: history, surveillance, antiretroviral therapy, and epidemiologic transition, 1984-2008.
    Ramos AN; Matida LH; Hearst N; Heukelbach J
    AIDS Patient Care STDS; 2011 Apr; 25(4):245-55. PubMed ID: 21413856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimisation of HIV care and service delivery: doing more with less.
    Boyd MA; Cooper DA
    Lancet; 2012 Nov; 380(9856):1860-6. PubMed ID: 22828482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AIDS, essential medicines, and compulsory licensing.
    Berman D
    J Int Assoc Physicians AIDS Care; 1999 Apr; 5(4):24-5. PubMed ID: 11367046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Implementation of a continuum of care for people living with HIV/AIDS in Hanoi (Vietnam)].
    de Loenzien M
    Sante; 2009; 19(3):141-8. PubMed ID: 20185390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brazilian response to the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among injection drug users.
    Mesquita F; Doneda D; Gandolfi D; Nemes MI; Andrade T; Bueno R; Piconez e Trigueiros D
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S382-5. PubMed ID: 14648452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 48. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. WHO initiatives to increase access to treatment in developing countries.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):57-8. PubMed ID: 14740603
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Making tenofovir accessible in the brazilian public health system: patent conflicts and generic production.
    Veras J
    Dev World Bioeth; 2014 Aug; 14(2):92-100. PubMed ID: 24889312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Public health. Global HIV/AIDS policy in transition.
    Bongaarts J; Over M
    Science; 2010 Jun; 328(5984):1359-60. PubMed ID: 20538936
    [No Abstract]   [Full Text] [Related]  

  • 52. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?
    Attaran A; Gillespie-White L
    JAMA; 2001 Oct; 286(15):1886-92. PubMed ID: 11597292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solidarity and AIDS: introduction.
    Krieger N
    Int J Health Serv; 1991; 21(3):505-10. PubMed ID: 1917210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research.
    Boyd MA; Cooper DA
    AIDS; 2007 Jul; 21 Suppl 4():S55-63. PubMed ID: 17620754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Merck broke AIDS drug price promise, says MSF.
    Ahmad K
    Lancet; 2004 Mar; 363(9412):872. PubMed ID: 15032243
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
    Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
    Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
    [No Abstract]   [Full Text] [Related]  

  • 58. A chorus of disapproval.
    Nature; 2008 Jul; 454(7204):551. PubMed ID: 18668050
    [No Abstract]   [Full Text] [Related]  

  • 59. AIDS meeting. Companies, donors pledge to close gap in AIDS treatment.
    Cohen J
    Science; 2000 Jul; 289(5478):368-9. PubMed ID: 10939936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The deafening silence of AIDS.
    Cameron E
    Health Hum Rights; 2000; 5(1):7-24. PubMed ID: 11154521
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.